2-Chloroadenosine modulates PAR-I and IL-23 expression and enhances docetaxel effects on PC3 cells

Prostate

Volumn 68, Issue 4, 2008, Pages 360-372

  Minelli, Alba ^a,d   Bellezza, Ilaria ^a   Tucci, Arianna ^a   Conte, Carmela ^a   Bracarda, Sergio ^b   Culig, Zoran ^c  

^a Dipartimento di Medicina Sperimentale Scienze Biochimiche   (Italy)

^b Ospedale Silvestrini   (Italy)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adenosine analogue; Immune system activation; Invasiveness; Metastatic potential; Prostate cancer

Indexed keywords

2 CHLOROADENOSINE; AGAR; DOCETAXEL; GONADORELIN AGONIST; INTERLEUKIN 23; MITOXANTRONE; PROTEINASE ACTIVATED RECEPTOR 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INVASION; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

2-CHLOROADENOSINE; AGAR; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-23 SUBUNIT P19; MALE; PROSTATIC NEOPLASMS; RECEPTOR, PAR-1; S PHASE; STEM CELLS; TAXOIDS;

EID: 40349091378     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20703     Document Type: Article

References (45)

1. Routh JC, Leibovich BC. Adenocarcinoma of the prostate: Epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 2005;80:899-907.
2. Msaouel P, Diamanti E, Tzanela M, Koutsilieris M. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opin Emerg Drugs 2007;12:285-299.
3. Rumohr JA, Chang SS. Current chemotherapeutic approaches for androgen-independent prostate cancer. Curr Opin Investig Drugs 2006;7:529-533.
4. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003;220:545-554.
5. Lam T, Hetherington JW, Greenman J, Maraveyas A. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 2006;17:113-121.
6. Mancuso A, Oudard S, Sternberg CN. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 2007;61:176-185.
7. Gilbert DC, Parker C. Docetaxel for the treatment of prostate cancer. Future Oncol 2005;1:307-314.
8. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001;61:443-448.
9. Jacobson KA, Hoffmann C, Cattabeni F, Abbracchio MP. Adenosine-induced cell death: Evidence for receptor-mediated signaling. Apoptosis 1999;4:197-211.
10. Minelli A, Bellezza I, Agostini M, Bracarda S, Culig Z. Mechanism of 2-chloroadenosine toxicity to PC3 cell line. Prostate 2006;66:1425-1436.
11. Bellezza I, Agostini M, Liguori L, Minelli A. Cytostatic effect of the nucleoside analogue 2-chloroadenosine on human prostate cancer cell line. Curr Pharm Anal 2005;1:265-272.
12. Locci P, Becchetti E, Pugliese M, Rossi L, Belcastro S, Calvitti M, Pietrarelli G, Staffolani N. Phenotype expression of human bone cells cultured on implant substrates. Cell Biochem Funct 1997; 15:163-170.
13. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-1399.
14. Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P. Thrombin receptor expression is upregulated in prostate cancer. Prostate 2006;66:273-282.
15. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-282.
16. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-725.
17. Kaye SB. Multidrug resistance: Clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998;10:S15-S19.
18. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-1171.
19. Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54:447-472.
20. Pastor-Anglada M, Felipe A, Casado FJ. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends Pharmacol Sci 1998;19:424-430.
21. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-9074.
22. Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 2002;20:4217-4224.
23. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-896.
24. Chandra J, Mansson E, Gogvadze V, Kaufmann SH, Albertioni F, Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood 2002;99:655-663.
25. D'Ambrosi N, Costanzi S, Angelini DF, Volpini R, Sancesario G, Cristalli G, Volonte C. 2-ClATP exerts anti-tumoural actions not mediated by P2 receptors in neuronal and glial cell lines. Biochem Pharmacol 2004;67:621-630.
26. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003;170:1709-1716.
27. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995;71:1194-1198.
28. Hess-Wilson JK, Daly HK, Zagorski WA, Montville CP, Knudsen KE. Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res 2006; 66:11998-12008.
29. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, Lin MF. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003;107:478-485.
30. Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, Rubin MA, Pienta KJ. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005;96:641-652.
31. Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate 2004;60:168-174.
32. Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH, Pienta KJ. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002;60:760-765.
33. Walz DA, Fenton JW. The role of thrombin in tumor cell metastasis. Invasion Metast 1994;14:303-308.
34. Ruf W, Fischer EG, Huang HY, Miyagi Y, Ott I, Riewald M, Mueller BM. Diverse functions of protease receptor tissue factor in inflammation and metastasis. Immunol Res 2000;21:289-292.
35. Lafleur MA, Hollenberg MD, Atkinson SJ, Uper VK, Murphy G, Edwards DR. Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. J Biochem 2001;357:107-115.
36. Katiyar SK. Matrix metalloproteinases in cancer metastasis: Molecular targets for prostate cancer prevention by green tea polyphenols and grape seed proanthocyanidins. Endocr Metab Immune Disord Drug Targets 2006;6:17-24.
37. Hong CI, West CR, Bernacki RJ, Tebbi CK, Berdel WE. 1-beta-D- arabinofuranosylcytosine conjugates of ether and thioether phospholipids. A new class of ara-C prodrug with improved antitumor activity. Lipids 1991;26:1437-1444.
38. Rabbani SA, Harakidas P, Bowlin T, Attardo G. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res 1998;58:3461-3465.
39. Fernandez-Calotti P, Gamberale R, Costas M, Sanchez Avalos J, Geffner J, Giordano M. Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway. Int Immunopharmacol 2006;6:715-723.
40. Reiter Z, Tomson S, Ozes ON, Taylor MW. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: Cytotoxic effect and MHC-unrestricted killer cell regulation. Blood 1993;81:1699-1708.
41. Conte E, Modica A, Cacopardo B, Messina L, Nigro L, Messina A. Ribavirin up-regulates IL-12 p40 gene expression and restores IL-12 levels in Leishmania-treated PBMCs. Parasite Immunol 2005;27:447-451.
42. Wang YQ, Ugai S, Shimozato O, Yu L, Kawamura K, Yamamoto H, Yamaguchi T, Saisho H, Tagawa M. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003;105:820-823.
43. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW, Roffler SR, Chiang BL, Lee CN, Wu CW, Tao MH. Antitumor and antimetastatic activity of IL-23. J Immunol 2003;171:600-607.
44. Shan BE, Yu L, Shimozato O, Tagawa M. Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. Anticancer Res 2004;24:79-82.
45. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effect of singledose interleukin-12 exposure on interleukin-12-associted toxicity and interferon-γ production. Blood 1997;90: 2541-2548.